Edition:
India

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

74.20EUR
20 Feb 2019
Change (% chg)

€-0.47 (-0.63%)
Prev Close
€74.67
Open
€74.66
Day's High
€74.75
Day's Low
€74.15
Volume
1,923,365
Avg. Vol
2,491,194
52-wk High
€80.44
52-wk Low
€62.88

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €108,903.00
Shares Outstanding(Mil.): 1,262.50
Dividend: 2.96
Yield (%): 3.43

Financials

  SASY.PA Industry Sector
P/E (TTM): 23.32 30.48 33.70
EPS (TTM): 3.70 -- --
ROI: 5.69 14.95 14.45
ROE: 8.50 16.27 15.96

Philippines revokes Sanofi's product license for dengue vaccine

MANILA The Philippines has permanently halted the sale, distribution and marketing of Sanofi's dengue vaccine in the country after the French drug maker failed to meet the directives of regulators.

19 Feb 2019

Sanofi and Regeneron cut list price of cholesterol drug by 60 percent

NEW YORK Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

11 Feb 2019

Sanofi and Regeneron cut list price of cholesterol drug by 60 pct

NEW YORK, Feb 11 Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

11 Feb 2019

UPDATE 2-France's Sanofi targets growth from new drugs after stronger quarter

PARIS, Feb 7 French drugmaker Sanofi on Thursday pledged further increases in full-year profit helped by new drug launches and its reorganisation efforts.

07 Feb 2019

Sanofi targets growth from new drug push

PARIS Sanofi on Thursday pledged further increases in full-year profits, helped by new drug launches and reorganisation efforts.

07 Feb 2019

REFILE-Sanofi's Genzyme lifts Q4 profits, expects more growth this year

PARIS, Feb 7 Sanofi posted slightly higher than expected fourth-quarter earnings on Thursday, helped by strong growth at its rare diseases Genzyme unit, and said it expected profits to rise again this year on the back of a revamped lineup of drugs.

07 Feb 2019

Sanofi blood disorder drug wins FDA approval

The U.S. Food and Drug Administration (FDA) said on Wednesday it had approved Sanofi SA's drug to treat a rare blood-clotting disorder in adults in combination with standard-of-care treatments.

06 Feb 2019

UPDATE 1-Sanofi blood disorder drug wins FDA approval

Feb 6 The U.S. Food and Drug Administration (FDA) said on Wednesday it had approved Sanofi SA's drug to treat a rare blood-clotting disorder in adults in combination with standard-of-care treatments.

06 Feb 2019

Sanofi blood disorder drug wins FDA approval

Feb 6 The U.S. Food and Drug Administration (FDA) said on Wednesday it had approved Sanofi SA's drug to treat a rare blood-clotting disorder in adults in combination with standard-of-care treatments.

06 Feb 2019

Undeterred by Sanofi's stumble, Takeda takes similar path with dengue shot

CHICAGO A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquito-borne disease that infects nearly 400 million people each year.

30 Jan 2019

Earnings vs. Estimates